Hi BrownHornet,
I saw the announcement somewhat differently so I am curious to hear the detail that forms your opinion. I have seen nothing to indicate American investors would be aware of Elanco sponsorship of a little oz company based in Perth, so why would it impact on their SP at this stage ?
Why do you think Elanco are going to ignore Pharmaust ? They have already signed away their rights after 6 months if they elect not to exercise their option. No waiting until 2020/2024 for their patent to expire. I suspect their competitors would love to get in under their guard.
Just trying to get a better handle on your comments.
All the Best
Pete
Ann: Appendix 4E & Preliminary Final Report, page-73
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $85.12M | |||
| Open | High | Low | Value | Volume |
| 17.5¢ | 18.0¢ | 17.5¢ | $27.32K | 155.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 49256 | 17.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 71665 | 6 |
View Market Depth
| Last trade - 10.54am 09/09/2024 (20 minute delay) ? |
| PAA (ASX) Chart |